On Monday, Krystal Biotech earned an upgrade to its Relative Strength (RS) Rating, from 88 to 91.
IBD's proprietary RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against all other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they begin their largest price moves.
Here Are 3 Keys For Successful Stock Investing
Krystal Biotech is trying to complete a consolidation with a 219.34 buy point. See if the stock can break out in heavy volume.
Krystal Biotech posted 0% earnings growth last quarter. Revenue gains came in at 879%.
Krystal Biotech holds the No. 8 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
